Basic information Safety Supplier Related

MY-5445

Basic information Safety Supplier Related

MY-5445 Basic information

Product Name:
MY-5445
Synonyms:
  • MY-5445
  • 1-(3-CHLOROPHENYLAMINO)-4-PHENYLPHTHALAZINE
  • 1-(3-CHLOROANILINO)-4-PHENYLPHTHALAZINE
  • N-(3-Chlorophenyl)-4-phenyl-1-phthalazinamine
  • N-(3-chlorophenyl)-4-phenylphthalazin-1-amine
  • MY 5445;MY5445
  • 1-(3-Chloroanilino)-4-phenylphthalazine >
  • aggregation,platelet,Inhibitor,anticancer,inhibit,MY5445,neuropathic,MY 5445,Phosphodiesterase (PDE),neuropathic pain,allodynia,MY-5445
CAS:
78351-75-4
MF:
C20H14ClN3
MW:
331.8
Product Categories:
  • Cyclic Nucleotide related
Mol File:
78351-75-4.mol
More
Less

MY-5445 Chemical Properties

Boiling point:
539.7±50.0 °C(Predicted)
Density 
1.310±0.06 g/cm3(Predicted)
storage temp. 
Store at RT
solubility 
DMF: 2 mg/ml; DMSO: 2 mg/ml; DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml
pka
4.91±0.30(Predicted)
form 
Yellow solid.
color 
White to Light yellow
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-36
HS Code 
2933.99.8290
More
Less

MY-5445 Usage And Synthesis

Description

MY-5445 is a selective inhibitor of the cyclic GMP (cGMP) phosphodiesterase, PDE5, with a Ki value of 1.3 μM. It inhibits calcium- and cAMP-selective PDEs with Ki values of >1,000 and 915 μM, respectively. MY-5445 has been shown to relax intact strips of rat aorta with an EC50 value of 4 μM.

Uses

MY-5445 is a selective cGMP phosphodiesterase inhibitor. Potent PDE5 inhibitor.

Definition

ChEBI: N-(3-chlorophenyl)-4-phenyl-1-phthalazinamine is a ring assembly and a member of pyridazines.

Biological Activity

Specific inhibitor of cyclic GMP phosphodiesterase, selective for PDE5 (IC 50 = 0.5 μ M).

in vivo

MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity[3].

Animal Model:C57BL/6J male mice[3]
Dosage:0.5 mg/kg, 3 mg/kg
Administration:Intraperitoneal injection, twice a day, for 15 days
Result:Alleviated the cuff-induced allodynia.

IC 50

PDE5: 1.3 μM (Ki); PDE5: 6.7 μM (IC50); PDE4: 37 μM (IC50)

References

[1] JOHN E. SOUNESS. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine[J]. British Journal of Pharmacology, 1989, 98 3: 725-734. DOI: 10.1111/j.1476-5381.1989.tb14599.x
[2] T YAMAMOTO. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase.[J]. The Journal of Biological Chemistry, 1983, 258 23: 14173-14177.

MY-5445Supplier

J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
ZHIWE CHEMTECH CO LTD
Tel
021-20221225 13917446399
Email
zwchem@163.com
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Email
Sales-CN@TCIchemicals.com
TOKYO CHEMICAL INDUSTRY CO., LTD.
Tel
03-36680489
Email
Sales-JP@TCIchemicals.com